The Study
We conducted a retrospective review of medical records from 2007-2017 from 2 national tertiary level hospitals in Panama City. Hospital Santo Tomás and Complejo Hospitalario Metropolitano Dr. Arnulfo Arias Madrid (CHMDrAAM) are the 2 main referral hospitals for Panama and are in the capital city.
We reviewed specimen registries from the microbiology laboratories at each institution; we also identified 1 case from a poster presented at a national scientific meeting. We included patients who had a culture-positive report for B. pseudomallei and a clinical diagnosis of melioidosis at discharge. We excluded 2 patients with culture-positive results for B. pseudomallei because their clinical diagnoses were not related to their test results.
The microbiology laboratories of Hospital Santo Tomás and CHDrAAM identified B. pseudomallei strains from blood culture by using BacT/ALERT 3D Microbial Identification System (bioMérieux, https://www.biomerieux.com). Both laboratories also obtained isolates of B. pseudomallei from clinical specimens inoculated in Columbia agar prepared with 5% sheep blood and in MacConkey agar. Both laboratories used the VITEK 2 (bioMérieux) system to identify strains, which were then sent to the national reference laboratory at Instituto Conmemorativo Gorgas de Estudios de la Salud in Panama City, Panama, for microbiology confirmation and antimicrobial susceptibility testing.
We used a standardized form to collect data and then entered data into an Excel (Microsoft, https:// www.microsoft.com) database for descriptive analysis. The Institutional Review Board of Hospital Santo Tomás reviewed and approved this study.
We identified 12 cases that occurred during 2007-2017: 8 in Hospital Santo Tomás and 4 in CHM-DrAAM. We obtained medical records for all but 1 case, for which we obtained data from a poster presented at the 37th American College of Physicians Annual Central America Chapter Meeting in Panama City, Panama, in 2015 (14) .
The mean age of cases was 50.3 years (SD ±12 years); most (9/12) patients were male. We noted bacteremia and sepsis in most (8/12) cases, pneumonia in 6 cases, and intraabdominal abscesses in 4 cases. Other signs and symptoms included endocarditis, meningitis, osteomyelitis, and septic arthritis (Table) . Diabetes mellitus was the predominant risk factor. Most patients came from rural areas or suburbs of Panama City (Figure) , and none reported travel outside of Panama.
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Rapid microbiologic identification of B. pseudomallei is necessary to initiate appropriate, life-saving treatments. However, laboratory results can take >48 hours, delaying appropriate antimicrobial drug therapy. Of the 7 patients in this study who survived, records showed they were treated with TMP/SMX or doxycycline, but the length of antimicrobial drug treatments were not noted in the records.
Conclusions
The increase in reports of melioidosis in the Americas requires greater awareness of this disease among clinicians, especially those caring for patients with diabetes. Melioidosis often is misdiagnosed as pulmonary tuberculosis and scrofula (10); we found 2 misidentified clinical cases in our study. More studies are needed to identify specific high-risk areas and transmission routes in the Americas. Such insights can inform earlier clinical suspicion and guide the formulation of prevention strategies.
Because the clinical signs and symptoms of melioidosis are nonspecific, microbiologic identification is crucial to diagnosis. Thus, improved laboratory capacity is critical to improve patient outcomes in affected areas to aid epidemiologic and antibiotic susceptibility surveillance efforts. Collaboration among countries in the region could drive efforts to describe the origins of this disease and the actual prevalence in the Americas.
Our study has limitations because we collected data retrospectively and only included the most severe cases in Panama. Melioidosis occurs more frequently in rural areas, and cases might not be identified because of the lack of laboratory or diagnostic tools. We provide a perspective on the processes that hinder our knowledge of this disease in Panama, such as lack of surveillance data and inadequate laboratory capacity. Our data justify the need for increased surveillance for melioidosis and reinforce the need for complete epidemiologic data and adequate strain storage for further genetic analysis. Epidemiologic studies of seroprevalence, environmental sampling, and increased access to PCR techniques and broth microdilution testing are needed to determine whether B. pseudomallei is endemic to Panama and to improve treatment outcomes.
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